Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents

Table 2 DAA treatment regimens and results (n = 180)

Characteristic (missing values n/%)	Valid values
Characteristic (missing values n/%)	n	%
Therapies total (2/1)	178
LDV, SOF	88	49
SOF, DCV	29	16
LDV, SOF, RBV	17	10
SOF, SMV	11	6
DSV, OBV, PTV, RTV, RBV	11	6
DSV, OBV, PTV, RTV	9	5
SOF, RBV	7	4
SOF, RBV, PEG-IFN	3	2
DCV, SOF, RBV	1	< 1
SOF, SMV, RBV	1	< 1
PEG-IFN, TVR, RBV	1	< 1
Therapy result
Directly after therapy (1/< 1)	179
ETR	173	97
Remission	6	3
Twelve weeks after therapy	180
SVR12	170	94
Remission/viral load unchanged	6	> 2
Relapse	4	> 3
Side effects (13/7)	167
None	110	66
Headaches, nausea, sleep disorder	43	26
Skin reactions	6	4
Anaemia	2	> 1
Depression, anxiety	2	> 1
Gastrointestinal disorders	2	> 1
Other^a	2	> 1

^aManifestation of advanced infection (hepatorenal syndrome n = 1, bleeding of oesophageal varices n = 1); DAA direct-acting antiviral agents, LDV ledipasvir, SOF sofosbuvir, DCV daclatasvir, RBV ribavirin, RTV ritonavir, SMV simeprevir, DSV dasabuvir, OBV ombitasvir, PTV paritaprevir, PEG-IFN pegylated interferon, TVR telaprevir, ETR end-of-treatment response, SVR12 sustained virologic response twelve weeks after therapy

ISSN: 1745-6673